Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease: an interview study
Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease: an interview study
Objectives: Transition from originator biological medicines to their biosimilar equivalents is now part of routine clinical practice, but there is little understanding of patient experiences, which influence adherence and overall satisfaction with care. Understanding this will help ensure future switches adequately address patients' concerns and expectations leading to better outcomes for all stakeholders. Method: 35 patients participating in a clinical trial including an open-label transition event from originator to biosimilar adalimumab, mimicking what would be encountered in a real-world setting, took part in semi-structured interviews exploring their experience of biosimilar transition. Results: Opinions expressed were often heterogeneous, but common experiences and themes were identified. Five themes were identified following thematic analysis. (1) Understanding and awareness of biosimilars: prior awareness of biosimilars and knowledge of the biosimilar concept was low, indicating a disparity between healthcare professionals and patients. (2) Motivation to undertake transition: patients accept a biosimilar transition to minimise drug expenditure. (3) Initial concerns: before undertaking biosimilar transition away from the brand they had experienced, anticipated loss of efficacy and adverse effects from the biosimilar were common concerns for patients. (4) Reassuring factors: trust in the healthcare team is critical to patient acceptance of biosimilars. Important reassurances include a point of contact, education about biosimilars and monitoring. (5) Experiences during the transition: on reflection, participants described consistent efficacy and tolerability (although 22 participants specifically mentioned injection pain) following brand transition. Conclusion: The majority of patients felt comfortable with future transition to another adalimumab biosimilar. Injection experience was an important component of patient satisfaction.
Clinical Trial, Controlled Clinical Trial, Drug Substitution, GASTROENTEROLOGY, Inflammatory bowel disease
ejhpharm-2022-003371
Young, David
05bfdb8c-9675-470a-9dcb-5af247e1b4ca
Cummings, Fraser
d1fea617-b125-4129-89d1-1bfb6d8d2dfe
Latter, Susan
83f100a4-95ec-4f2e-99a5-186095de2f3b
Young, David
05bfdb8c-9675-470a-9dcb-5af247e1b4ca
Cummings, Fraser
d1fea617-b125-4129-89d1-1bfb6d8d2dfe
Latter, Susan
83f100a4-95ec-4f2e-99a5-186095de2f3b
Young, David, Cummings, Fraser and Latter, Susan
(2022)
Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease: an interview study.
European Journal of Hospital Pharmacy, , [003371].
(doi:10.1136/ejhpharm-2022-003371).
Abstract
Objectives: Transition from originator biological medicines to their biosimilar equivalents is now part of routine clinical practice, but there is little understanding of patient experiences, which influence adherence and overall satisfaction with care. Understanding this will help ensure future switches adequately address patients' concerns and expectations leading to better outcomes for all stakeholders. Method: 35 patients participating in a clinical trial including an open-label transition event from originator to biosimilar adalimumab, mimicking what would be encountered in a real-world setting, took part in semi-structured interviews exploring their experience of biosimilar transition. Results: Opinions expressed were often heterogeneous, but common experiences and themes were identified. Five themes were identified following thematic analysis. (1) Understanding and awareness of biosimilars: prior awareness of biosimilars and knowledge of the biosimilar concept was low, indicating a disparity between healthcare professionals and patients. (2) Motivation to undertake transition: patients accept a biosimilar transition to minimise drug expenditure. (3) Initial concerns: before undertaking biosimilar transition away from the brand they had experienced, anticipated loss of efficacy and adverse effects from the biosimilar were common concerns for patients. (4) Reassuring factors: trust in the healthcare team is critical to patient acceptance of biosimilars. Important reassurances include a point of contact, education about biosimilars and monitoring. (5) Experiences during the transition: on reflection, participants described consistent efficacy and tolerability (although 22 participants specifically mentioned injection pain) following brand transition. Conclusion: The majority of patients felt comfortable with future transition to another adalimumab biosimilar. Injection experience was an important component of patient satisfaction.
Text
Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease – an interview study
- Accepted Manuscript
More information
Accepted/In Press date: 28 June 2022
e-pub ahead of print date: 19 July 2022
Additional Information:
Funding Information:
FC has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Sandoz, Biogen, Samsung, Takeda, Bristol Myers Squibb and Galapagos. He has received research funding from Biogen, Amgen, Hospira/Pfizer, Celltrion, Janssen, GSK and AZ. SL has received funding for speaking at a symposium sponsored by MSD. DY has received support for travel, accommodation and conference attendance from Sandoz.
Publisher Copyright:
© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Keywords:
Clinical Trial, Controlled Clinical Trial, Drug Substitution, GASTROENTEROLOGY, Inflammatory bowel disease
Identifiers
Local EPrints ID: 468991
URI: http://eprints.soton.ac.uk/id/eprint/468991
ISSN: 2047-9956
PURE UUID: ba121218-882d-41f1-b234-46c3225268ef
Catalogue record
Date deposited: 02 Sep 2022 19:11
Last modified: 17 Mar 2024 02:51
Export record
Altmetrics
Contributors
Author:
David Young
Author:
Fraser Cummings
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
